Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LW402 Tablets for Moderate to Severe Atopic Dermatitis (Phase III, China)
CTR20260288Phase 3Active
- Sponsor
- Shanghai Changsen Pharmaceutical
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lw402 in atopic dermatitis (AD), sponsored by Shanghai Changsen Pharmaceutical. Started Mar 2026; status: active.
02
Drugs
lw402
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20260288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260288.